News

India Seeks New Frontiers for Pharma Exports Amid U.S. Tariff Uncertainty

This strategy is set to feature prominently at the upcoming International Pharmaceutical Exhibition in New Delhi, where Indian officials will host regulators and delegations from several countries to discuss opportunities for expanding cooperation.

• By Newsdesk
• New Delhi
• Sep 04, 2025

News

India is recalibrating its pharmaceutical export strategy as fears of potential U.S. tariffs weigh on the country’s largest export market for medicines. Although Washington has not imposed duties on Indian pharmaceuticals so far, the volatility of trade relations has prompted New Delhi to take precautionary steps to safeguard the sector. Government officials are working closely with industry stakeholders to diversify export destinations, with Brazil, Russia and the Netherlands being identified as priority markets to reduce the country’s reliance on the United States.

The U.S. currently accounts for more than one-third of India’s pharma exports, valued at about $10.5 billion in the last financial year. While this market has delivered strong growth, policymakers view the concentration as a vulnerability that could expose India to sudden disruptions if trade measures change. The government is therefore seeking to rebalance its export portfolio by supporting companies in navigating regulatory frameworks and market entry challenges in alternative geographies.

This strategy is set to feature prominently at the upcoming International Pharmaceutical Exhibition in New Delhi, where Indian officials will host regulators and delegations from several countries to discuss opportunities for expanding cooperation. According to policy planners, such platforms are essential to easing approval processes, aligning quality standards, and ensuring smoother access for Indian generic medicines in overseas markets.

Parallel efforts are underway to deepen engagement with the United Kingdom under the recently signed free trade agreement. Officials expect that the pact will open new avenues for Indian drugmakers, particularly in supplying generics and active pharmaceutical ingredients to the U.K.’s National Health Service. By building stronger bilateral trade frameworks, New Delhi hopes to create more predictable demand channels for its pharmaceutical industry.

The broader policy approach reflects India’s determination to maintain its role as a trusted global supplier of affordable medicines while insulating the sector from geopolitical and trade-related risks. By advancing regulatory diplomacy and leveraging trade agreements, India is positioning its pharmaceutical industry to remain resilient even as uncertainties continue in its most important export market.